Cargando…

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib

Detalles Bibliográficos
Autores principales:	Yun, Hwan-Jung, Seo, Young Joon, Lee, Hyo Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Dermatological Association; The Korean Society for Investigative Dermatology 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695446/ https://www.ncbi.nlm.nih.gov/pubmed/26719663 http://dx.doi.org/10.5021/ad.2015.27.6.791

Ejemplares similares

Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Böhm, Steffen, et al.
Publicado: (2010)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall dermatitis
por: Li, Jun, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
por: Carter, Joanne J., et al.
Publicado: (2017)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
por: Li, Haifu, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

A Study of Association of Premature Graying of Hair and Osteopenia in North Indian Population
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2020)

MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases
por: Park, Hyun Jin, et al.
Publicado: (2022)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in Cardiomyocytes
por: Chang, Wei-Ting, et al.
Publicado: (2020)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer
por: Gao, Zhenzhen, et al.
Publicado: (2020)

Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
por: Kanaan, Rana, et al.
Publicado: (2017)

Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib
por: Lee, Sun Young, et al.
Publicado: (2018)

Rapid hair depigmentation in patient treated with pazopanib
por: Šeparović, Robert, et al.
Publicado: (2018)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

An Observational, Epidemiological Study on Pattern of Clinical Presentation and Associated Laboratory Findings in Patients of Premature Hair Graying
por: Mediratta, Vibhu, et al.
Publicado: (2018)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
por: Benner, Brooke, et al.
Publicado: (2021)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration
por: Yang, Yongliang, et al.
Publicado: (2015)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials
por: Qu, Kai, et al.
Publicado: (2016)

The Pattern of Hair Dyeing in Koreans with Gray Hair
por: Jo, Seong Jin, et al.
Publicado: (2013)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Schöffski, P, et al.
Publicado: (2010)

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor
por: Nie, Guangyan, et al.
Publicado: (2021)

Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China
por: Chen, Yilin, et al.
Publicado: (2022)

Gray Hairs
Publicado: (1893)

Cannot write session to /tmp/vufind_sessions/sess_o9sa3vl1lbq3eus8c9qcu5q6dh